In its Measuring the Return from Pharmaceutical and Innovation series, Deloitte reported on its first nine years with a focused examination of the top 12 pharmaceutical companies. Its analysis uncovered declining trends in R&D returns throughout the biopharma industry. In…

The race to find subjects that meet the various criteria for involvement in clinical trials occasionally overwhelms the more empathetic side of the enrollment equation. With large dollar amounts invested in drug development and an intrinsic need to be faster…